Why more data is needed before we pin our hopes on Pfizer’s Covid vaccine breakthrough

Three experts involved in Australia’s roll out on why expectations should be tempered

A woman wears a face mask as she walks by the Pfizer world headquarters in New York.
Three experts involved in Australia’s roll out on why expectations should be tempered
(Image credit: Kena Betancur/AFP via Getty Images)

Harry Al-Wassiti, research fellow at Monash University, Colin Pouton, professor of pharmaceutical biology at Monash University, and Kylie Quinn, vice-chancellor’s research fellow at RMIT University, on what the Pfizer vaccine results mean for the pandemic.

German biotech company BioNTech and US pharmaceutical Pfizer announced on Monday promising early results from their phase 3 clinical trial for a vaccine against SARS-CoV-2, the virus that causes Covid-19.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up